Lipid nanoparticle formulations for delivery of MRNA
The present invention provides, among other things, compositions and methods of formulating nucleic acid-containing nanoparticles comprising no more than three distinct lipids components, one distinct lipid component being a sterol-based cationic lipid. In some embodiments, the present invention provides compositions and methods in which the lipid nanoparticles further comprise helper lipids and PEG-modified lipids. The resulting formulation comprises a high encapsulation percentage for nucleic acids.
1. A method of delivering messenger RNAs (mRNAs) encoding a protein or a peptide in vivo comprising administering by pulmonary delivery to a subject in need of delivery a composition comprising:
the mRNAs; and
lipid nanoparticles encapsulating the mRNAs, wherein each individual lipid nanoparticle comprises no more than three distinct lipid components, wherein the three lipid components are a non-cationic lipid, a PEG-modified lipid, and a sterol-based cationic lipid, wherein the sterol-based cationic lipid has a structure according to Formula (A),
B-L 1 -S (Formula A),
or a protonated form thereof, wherein:
B is a basic functional group selected from
dialkylamino and guanidine;
L 1 is an optionally substituted linker group; and
S is a sterol.
2. The method of claim 1 , wherein the mRNAs are codon-optimized and/or comprise one or more modified nucleotides.
3. The method of claim 1 , wherein the lipid nanoparticles have a size less than about 100 nm.
4. The method of claim 1 , wherein the lipid nanoparticles have a lipid/mRNA (N/P) ratio of 2 or 4.
5. The method of claim 1 , wherein the molar percentage of the PEG-modified lipid in the lipid nanoparticles is no more than 5%.
6. The method of claim 1 , wherein the molar percentage of the sterol-based cationic lipid in the lipid nanoparticles is no more than 70%.
7. The method of claim 1 , wherein the molar percentage of the sterol-based cationic lipid in the lipid nanoparticles is at least 40%.
8. A composition comprising:
messenger RNAs (mRNAs) encoding a protein or a peptide; and
lipid nanoparticles encapsulating the mRNAs, wherein each individual lipid nanoparticle comprises no more than three distinct lipid components, wherein the three lipid components are a non-cationic lipid, a PEG-modified lipid, and a sterol-based cationic lipid, wherein the sterol-based cationic lipid has a structure according to Formula (A),
B-L 1 -S (Formula A),
or a protonated form thereof, wherein:
B is a basic functional group selected from
dialkylamino and guanidine;
L 1 is an optionally substituted linker group; and
S is a sterol, and
further wherein the lipid nanoparticles have an encapsulation percentage for mRNAs of at least 70%.
9. The composition of claim 8 , wherein the sterol-based cationic lipid constitutes no more than 70% of the total lipids.
10. The composition of claim 8 , wherein L′ is an optionally substituted linker group that is a C 1 -C 20 alkylene or a 2- to 20-membered heteroalkylene.
11. The composition of claim 8 , wherein L′ does not comprise substituents having the structure-N(R′) 2 , or a positively charged form thereof, wherein each R′ is independently hydrogen or optionally substituted C 1 -C 20 alkyl.
12. The composition of claim 8 , wherein S is a sterol selected from a zoosterol, or an oxidized or reduced form thereof, a phytosterol, or an oxidized or reduced form thereof, a synthetic sterol, or an oxidized or reduced form thereof, cholesterol, an oxidized form of cholesterol, a reduced form of cholesterol, alkyl lithocholate, stigmasterol, stigmastanol, campesterol, ergosterol, and sitosterol.
13. The composition of claim 8 , wherein the mRNAs are codon-optimized and/or comprise one or more modified nucleotides.
14. The composition of claim 8 , wherein the lipid nanoparticles have a lipid/mRNA (N/P) ratio of 2 or 4.
15. The composition of claim 8 , wherein the molar percentage of the PEG-modified lipid in the lipid nanoparticles is no more than 5%.
16. The composition of claim 8 , wherein the molar percentage of the sterol-based cationic lipid in the lipid nanoparticles is no more than 70%.
17. The composition of claim 8 , wherein the molar percentage of the sterol-based cationic lipid in the lipid nanoparticles is at least 40%.